Medicare coverage for CAR-T drugs on the horizonMedicare could soon cover CAR-T therapies under new proposals from the US’ Centers for Medicare & Medicaid Services Share XMedicare coverage for CAR-T drugs on the horizonhttps://pharmaphorum.com/news/medicare-coverage-for-car-t-drugs-on-the-horizon/
Oncology round-up: CAR-T conference raises hopes for solid tumour therapyKisaco Research’s CAR-T Congress EU could not have come at a better time – the day after it Share XOncology round-up: CAR-T conference raises hopes for solid tumour therapyhttps://pharmaphorum.com/views-and-analysis/oncology-round-up-car-t-conference-raises-hopes-for-solid-tumour-therapy/
NICE approves Novartis’ CAR-T therapy for diffuse large B-cell lymphomaNICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did Share XNICE approves Novartis’ CAR-T therapy for diffuse large B-cell lymphomahttps://pharmaphorum.com/news/nice-approves-novartis-car-t-therapy-for-diffuse-large-b-cell-lymphoma/
Brexit could hinder CAR-T reimbursement in EuropeBrexit and the rise of nationalism in Europe could hinder patients’ access to pricey CAR-T therapies across Europe, Share XBrexit could hinder CAR-T reimbursement in Europehttps://pharmaphorum.com/news/brexit-could-hinder-car-t-reimbursement-in-europe/
Doctors and patient groups struggle with CAR-T ‘hype’Managing patients’ expectations of CAR-T therapies is proving to be a huge challenge from when selection decisions are Share XDoctors and patient groups struggle with CAR-T ‘hype’https://pharmaphorum.com/news/doctors-and-patient-groups-struggle-with-car-t-hype/
CAR-T firms push to improve manufacturing efficiencyExperience with the approved CAR-T drugs from Novartis and Gilead has shown that being able to manufacture enough Share XCAR-T firms push to improve manufacturing efficiencyhttps://pharmaphorum.com/news/car-t-firms-push-to-improve-manufacturing-efficiency/
Hope for CAR-T combination that could tackle solid tumoursGetting CAR-T cells to work in solid tumours is proving a tough nut to crack – and a Share XHope for CAR-T combination that could tackle solid tumourshttps://pharmaphorum.com/news/hope-for-car-t-combination-that-could-tackle-solid-tumours/
Takeda strikes three new immuno-oncology dealsTakeda is upping its commitment to cancer after its Shire takeover with the announcement of three new research Share XTakeda strikes three new immuno-oncology dealshttps://pharmaphorum.com/news/takeda-strikes-three-new-immuno-oncology-deals/
Novartis offers to buy Kymriah manufacturerFollowing its success in the burgeoning area of CAR-T therapies, Novartis is looking to strengthen its cell and Share XNovartis offers to buy Kymriah manufacturerhttps://pharmaphorum.com/news/novartis-offers-to-buy-kymriah-manufacturer/
